194 related articles for article (PubMed ID: 29910056)
1. Rationale and Design of the SENECA (StEm cell iNjECtion in cAncer survivors) Trial.
Bolli R; Hare JM; Henry TD; Lenneman CG; March KL; Miller K; Pepine CJ; Perin EC; Traverse JH; Willerson JT; Yang PC; Gee AP; Lima JA; Moyé L; Vojvodic RW; Sayre SL; Bettencourt J; Cohen M; Ebert RF; Simari RD;
Am Heart J; 2018 Jul; 201():54-62. PubMed ID: 29910056
[TBL] [Abstract][Full Text] [Related]
2. Allogeneic Mesenchymal Cell Therapy in Anthracycline-Induced Cardiomyopathy Heart Failure Patients: The CCTRN SENECA Trial.
Bolli R; Perin EC; Willerson JT; Yang PC; Traverse JH; Henry TD; Pepine CJ; Mitrani RD; Hare JM; Murphy MP; March KL; Ikram S; Lee DP; O'Brien C; Durand JB; Miller K; Lima JA; Ostovaneh MR; Ambale-Venkatesh B; Gee AP; Richman S; Taylor DA; Sayre SL; Bettencourt J; Vojvodic RW; Cohen ML; Simpson LM; Lai D; Aguilar D; Loghin C; Moyé L; Ebert RF; Davis BR; Simari RD;
JACC CardioOncol; 2020 Nov; 2(4):581-595. PubMed ID: 33403362
[TBL] [Abstract][Full Text] [Related]
3. Comparison of allogeneic vs autologous bone marrow–derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial.
Hare JM; Fishman JE; Gerstenblith G; DiFede Velazquez DL; Zambrano JP; Suncion VY; Tracy M; Ghersin E; Johnston PV; Brinker JA; Breton E; Davis-Sproul J; Schulman IH; Byrnes J; Mendizabal AM; Lowery MH; Rouy D; Altman P; Wong Po Foo C; Ruiz P; Amador A; Da Silva J; McNiece IK; Heldman AW; George R; Lardo A
JAMA; 2012 Dec; 308(22):2369-79. PubMed ID: 23117550
[TBL] [Abstract][Full Text] [Related]
4. Rationale and design of the first randomized, double-blind, placebo-controlled trial of intramyocardial injection of autologous bone-marrow derived Mesenchymal Stromal Cells in chronic ischemic Heart Failure (MSC-HF Trial).
Mathiasen AB; Jørgensen E; Qayyum AA; Haack-Sørensen M; Ekblond A; Kastrup J
Am Heart J; 2012 Sep; 164(3):285-91. PubMed ID: 22980293
[TBL] [Abstract][Full Text] [Related]
5. Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trial.
Heldman AW; DiFede DL; Fishman JE; Zambrano JP; Trachtenberg BH; Karantalis V; Mushtaq M; Williams AR; Suncion VY; McNiece IK; Ghersin E; Soto V; Lopera G; Miki R; Willens H; Hendel R; Mitrani R; Pattany P; Feigenbaum G; Oskouei B; Byrnes J; Lowery MH; Sierra J; Pujol MV; Delgado C; Gonzalez PJ; Rodriguez JE; Bagno LL; Rouy D; Altman P; Foo CW; da Silva J; Anderson E; Schwarz R; Mendizabal A; Hare JM
JAMA; 2014 Jan; 311(1):62-73. PubMed ID: 24247587
[TBL] [Abstract][Full Text] [Related]
6. A Phase II study of autologous mesenchymal stromal cells and c-kit positive cardiac cells, alone or in combination, in patients with ischaemic heart failure: the CCTRN CONCERT-HF trial.
Bolli R; Mitrani RD; Hare JM; Pepine CJ; Perin EC; Willerson JT; Traverse JH; Henry TD; Yang PC; Murphy MP; March KL; Schulman IH; Ikram S; Lee DP; O'Brien C; Lima JA; Ostovaneh MR; Ambale-Venkatesh B; Lewis G; Khan A; Bacallao K; Valasaki K; Longsomboon B; Gee AP; Richman S; Taylor DA; Lai D; Sayre SL; Bettencourt J; Vojvodic RW; Cohen ML; Simpson L; Aguilar D; Loghin C; Moyé L; Ebert RF; Davis BR; Simari RD;
Eur J Heart Fail; 2021 Apr; 23(4):661-674. PubMed ID: 33811444
[TBL] [Abstract][Full Text] [Related]
7. Intramyocardial transplantation of mesenchymal stromal cells for chronic myocardial ischemia and impaired left ventricular function: Results of the MESAMI 1 pilot trial.
Guijarro D; Lebrin M; Lairez O; Bourin P; Piriou N; Pozzo J; Lande G; Berry M; Le Tourneau T; Cussac D; Sensebe L; Gross F; Lamirault G; Huynh A; Manrique A; Ruidavet JB; Elbaz M; Trochu JN; Parini A; Kramer S; Galinier M; Lemarchand P; Roncalli J
Int J Cardiol; 2016 Apr; 209():258-65. PubMed ID: 26901787
[TBL] [Abstract][Full Text] [Related]
8. Randomized Comparison of Allogeneic Versus Autologous Mesenchymal Stem Cells for Nonischemic Dilated Cardiomyopathy: POSEIDON-DCM Trial.
Hare JM; DiFede DL; Rieger AC; Florea V; Landin AM; El-Khorazaty J; Khan A; Mushtaq M; Lowery MH; Byrnes JJ; Hendel RC; Cohen MG; Alfonso CE; Valasaki K; Pujol MV; Golpanian S; Ghersin E; Fishman JE; Pattany P; Gomes SA; Delgado C; Miki R; Abuzeid F; Vidro-Casiano M; Premer C; Medina A; Porras V; Hatzistergos KE; Anderson E; Mendizabal A; Mitrani R; Heldman AW
J Am Coll Cardiol; 2017 Feb; 69(5):526-537. PubMed ID: 27856208
[TBL] [Abstract][Full Text] [Related]
9. Rationale and Design of the CONCERT-HF Trial (Combination of Mesenchymal and c-kit
Bolli R; Hare JM; March KL; Pepine CJ; Willerson JT; Perin EC; Yang PC; Henry TD; Traverse JH; Mitrani RD; Khan A; Hernandez-Schulman I; Taylor DA; DiFede DL; Lima JAC; Chugh A; Loughran J; Vojvodic RW; Sayre SL; Bettencourt J; Cohen M; Moyé L; Ebert RF; Simari RD;
Circ Res; 2018 Jun; 122(12):1703-1715. PubMed ID: 29703749
[TBL] [Abstract][Full Text] [Related]
10. Rationale and design of the Transendocardial Injection of Autologous Human Cells (bone marrow or mesenchymal) in Chronic Ischemic Left Ventricular Dysfunction and Heart Failure Secondary to Myocardial Infarction (TAC-HFT) trial: A randomized, double-blind, placebo-controlled study of safety and efficacy.
Trachtenberg B; Velazquez DL; Williams AR; McNiece I; Fishman J; Nguyen K; Rouy D; Altman P; Schwarz R; Mendizabal A; Oskouei B; Byrnes J; Soto V; Tracy M; Zambrano JP; Heldman AW; Hare JM
Am Heart J; 2011 Mar; 161(3):487-93. PubMed ID: 21392602
[TBL] [Abstract][Full Text] [Related]
11. Safety and Efficacy of the Intravenous Infusion of Umbilical Cord Mesenchymal Stem Cells in Patients With Heart Failure: A Phase 1/2 Randomized Controlled Trial (RIMECARD Trial [Randomized Clinical Trial of Intravenous Infusion Umbilical Cord Mesenchymal Stem Cells on Cardiopathy]).
Bartolucci J; Verdugo FJ; González PL; Larrea RE; Abarzua E; Goset C; Rojo P; Palma I; Lamich R; Pedreros PA; Valdivia G; Lopez VM; Nazzal C; Alcayaga-Miranda F; Cuenca J; Brobeck MJ; Patel AN; Figueroa FE; Khoury M
Circ Res; 2017 Oct; 121(10):1192-1204. PubMed ID: 28974553
[TBL] [Abstract][Full Text] [Related]
12. Rationale and design of a randomized controlled trial of allogeneic mesenchymal stem cells in patients with nonischemic cardiomyopathy.
Greene SJ; Epstein SE; Kim RJ; Quyyumi AA; Cole RT; Anderson AS; Wilcox JE; Skopicki HA; Sikora S; Verkh L; Tankovich NI; Gheorghiade M; Butler J
J Cardiovasc Med (Hagerstown); 2017 Apr; 18(4):283-290. PubMed ID: 26479144
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Mesenchymal Stem Cell Efficacy in Ischemic Versus Nonischemic Dilated Cardiomyopathy.
Tompkins BA; Rieger AC; Florea V; Banerjee MN; Natsumeda M; Nigh ED; Landin AM; Rodriguez GM; Hatzistergos KE; Schulman IH; Hare JM
J Am Heart Assoc; 2018 Jul; 7(14):. PubMed ID: 30005555
[TBL] [Abstract][Full Text] [Related]
14. Rationale and design of the European multicentre study on Stem Cell therapy in IschEmic Non-treatable Cardiac diseasE (SCIENCE).
Paitazoglou C; Bergmann MW; Vrtovec B; Chamuleau SAJ; van Klarenbosch B; Wojakowski W; Michalewska-Włudarczyk A; Gyöngyösi M; Ekblond A; Haack-Sørensen M; Jaquet K; Vrangbaek K; Kastrup J;
Eur J Heart Fail; 2019 Aug; 21(8):1032-1041. PubMed ID: 30790396
[TBL] [Abstract][Full Text] [Related]
15. The ixCELL-DCM Trial: Rationale and Design.
Henry TD; Schaer GL; DeMaria A; Recker D; Remmers AE; Goodrich J; Patel AN
Cell Transplant; 2016; 25(9):1689-1699. PubMed ID: 27009022
[TBL] [Abstract][Full Text] [Related]
16. Intravenous Allogeneic Mesenchymal Stem Cells for Nonischemic Cardiomyopathy: Safety and Efficacy Results of a Phase II-A Randomized Trial.
Butler J; Epstein SE; Greene SJ; Quyyumi AA; Sikora S; Kim RJ; Anderson AS; Wilcox JE; Tankovich NI; Lipinski MJ; Ko YA; Margulies KB; Cole RT; Skopicki HA; Gheorghiade M
Circ Res; 2017 Jan; 120(2):332-340. PubMed ID: 27856497
[TBL] [Abstract][Full Text] [Related]
17. Dose Comparison Study of Allogeneic Mesenchymal Stem Cells in Patients With Ischemic Cardiomyopathy (The TRIDENT Study).
Florea V; Rieger AC; DiFede DL; El-Khorazaty J; Natsumeda M; Banerjee MN; Tompkins BA; Khan A; Schulman IH; Landin AM; Mushtaq M; Golpanian S; Lowery MH; Byrnes JJ; Hendel RC; Cohen MG; Valasaki K; Pujol MV; Ghersin E; Miki R; Delgado C; Abuzeid F; Vidro-Casiano M; Saltzman RG; DaFonseca D; Caceres LV; Ramdas KN; Mendizabal A; Heldman AW; Mitrani RD; Hare JM
Circ Res; 2017 Nov; 121(11):1279-1290. PubMed ID: 28923793
[TBL] [Abstract][Full Text] [Related]
18. Bone marrow-derived mesenchymal stromal cell treatment in patients with severe ischaemic heart failure: a randomized placebo-controlled trial (MSC-HF trial).
Mathiasen AB; Qayyum AA; Jørgensen E; Helqvist S; Fischer-Nielsen A; Kofoed KF; Haack-Sørensen M; Ekblond A; Kastrup J
Eur Heart J; 2015 Jul; 36(27):1744-53. PubMed ID: 25926562
[TBL] [Abstract][Full Text] [Related]
19. Effect of allogeneic adipose tissue-derived mesenchymal stromal cell treatment in chronic ischaemic heart failure with reduced ejection fraction - the SCIENCE trial.
Qayyum AA; van Klarenbosch B; Frljak S; Cerar A; Poglajen G; Traxler-Weidenauer D; Nadrowski P; Paitazoglou C; Vrtovec B; Bergmann MW; Chamuleau SAJ; Wojakowski W; Gyöngyösi M; Kraaijeveld A; Hansen KS; Vrangbaek K; Jørgensen E; Helqvist S; Joshi FR; Johansen EM; Follin B; Juhl M; Højgaard LD; Mathiasen AB; Ekblond A; Haack-Sørensen M; Kastrup J;
Eur J Heart Fail; 2023 Apr; 25(4):576-587. PubMed ID: 36644821
[TBL] [Abstract][Full Text] [Related]
20. A Combination of Allogeneic Stem Cells Promotes Cardiac Regeneration.
Natsumeda M; Florea V; Rieger AC; Tompkins BA; Banerjee MN; Golpanian S; Fritsch J; Landin AM; Kashikar ND; Karantalis V; Loescher VY; Hatzistergos KE; Bagno L; Sanina C; Mushtaq M; Rodriguez J; Rosado M; Wolf A; Collon K; Vincent L; Kanelidis AJ; Schulman IH; Mitrani R; Heldman AW; Balkan W; Hare JM
J Am Coll Cardiol; 2017 Nov; 70(20):2504-2515. PubMed ID: 29145950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
